Medicines Marketed by Cipla Ltd

About Cipla Ltd

Cipla Ltd is a leading pharmaceutical company that has been operating in the industry since 1935. Headquartered in Mumbai, Maharashtra, India, Cipla has established a strong global presence, with its products available in over 65 therapeutic categories and more than 50 dosage forms. The company's largest market is India, followed by Africa and North America, and its operations extend to various countries, including the US, Canada, and South Africa.

Cipla is dedicated to providing access to quality and affordable medicines across multiple therapeutic areas, catering to a wide range of healthcare needs worldwide. With its extensive experience in producing over 200 generics and complex active pharmaceutical ingredients (APIs), which are distributed across 60 countries, Cipla has become a trusted name in the pharmaceutical industry.

Cipla Ltd Products

Cipla Ltd offers a comprehensive portfolio of pharmaceutical products, including active pharmaceutical ingredients (APIs), generic and branded generic medicines, biosimilars, and consumer healthcare products. The company's subsidiary, Cipla BioTec Private Ltd., focuses on the development and manufacturing of biosimilars, while Cipla Healthcare Ltd., a wholly-owned subsidiary, specialises in consumer health products, including nutritional supplements like Endura Mass, which was acquired in 2022.

Some of the key therapeutic areas covered by Cipla's products include cardiovascular diseases, dermatology and cosmetology, HIV/AIDS, diabetes, respiratory conditions, and infectious diseases. The company is known for its innovative products, such as the four-in-one antiretroviral treatment launched in partnership with the Drugs for Neglected Diseases initiative (DNDi) in 2022, and its metered-dose inhaler devices, spacers, and related products, particularly under the business unit Cipla Global Access. Cipla also offers diagnostic devices and treatments for various infectious diseases, including COVID-19 medications like Cipmolnu (Molnupiravir). With over 1,300 scientists working on developing new products, improving existing ones, and expanding product applications, Cipla continues to demonstrate its commitment to innovation and sustainability in the pharmaceutical industry.